MPD: List measures where strain DBA/2J is an outlier

List measures where DBA/2J is an outlier

Click on pulldowns below to see DBA/2J means with summary statistic tooltips.
Within each pulldown, the "up" and "down" triangles indicate when this strain is an outlier.
You can also download all phenotypes for this strain and sort by Z score in Excel.

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Auwerx1:59	Auwerx1	monitoring system	high-fat diet	oxygen consumption, 24h period, during day [mL/kg/min] vo2_day 111238 CD HFD	BXD w/par	53	m	16wks	N=4	2016

Auwerx1:85	Auwerx1	hormone quantification	high-fat diet	insulin baseline, glucose tolerance test (pregavage, overnight fast) [µg/L] ogtt_ins_t0 111264 CD HFD	BXD w/par	57	m	17wks	N=4	2016

Auwerx1:125	Auwerx1	monitoring system	high-fat diet	horizontal activity (beam breaks) at night, basal activity test, for 48h [n/h] horiz_act 111304 CD HFD	BXD w/par	57	m	23wks	N=4	2016

Auwerx1:127	Auwerx1	monitoring system	high-fat diet	vertical activity (beam breaks) at night, basal activity test, for 48h [n/h] vert_act 111306 CD HFD	BXD w/par	57	m	23wks	N=4	2016

Auwerx1:141	Auwerx1	running wheel monitoring	high-fat diet	distance traveled, voluntary wheel running test, last 24h [km] dist_wheel 111320 CD HFD	BXD w/par	57	m	23wks	N=4	2016

Auwerx1:153	Auwerx1	monitoring system	high-fat diet	maximum oxygen consumption, second treadmill training [mL/kg/min] vo2_max_treadmill2 111332 CD HFD	BXD w/par	57	m	25wks	N=4	2016

Auwerx1:155	Auwerx1	treadmill endurance test	high-fat diet	distance traveled, second treadmill training [m] dist_treadmill2 111334 CD HFD	BXD w/par	57	m	25wks	N=4	2016

Auwerx1:175	Auwerx1	lipid profile	high-fat diet	blood free fatty acids amount [mmol/L] fatty_acids 111354 CD HFD	BXD w/par	54	m	29wks	N=4	2016

Auwerx1:181	Auwerx1	metabolic panel	high-fat diet	blood iron amount [µmol/L] iron 111360 CD HFD	BXD w/par	54	m	29wks	N=4	2016

Auwerx1:193	Auwerx1	lipid profile	high-fat diet	blood triglyceride amount [mmol/L] triglyc 111372 CD HFD	BXD w/par	54	m	29wks	N=4	2016

Auwerx1:213	Auwerx1	cell signaling molecule detection	high-fat diet	blood tumor necrosis factor alpha (TNF alpha) amount [pg/mL] tnf_alpha 111392 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:225	Auwerx1	organ weights	high-fat diet	kidney weight (both) [g] kidney_wt 111404 CD HFD	BXD w/par	57	m	29wks	N=4	2016

Auwerx2:77	Auwerx2	hormone quantification	(none)	insulin, glucose tolerance test (20% glucose oral gavage, overnight fast), after 30 min [µg/L] ogtt_ins_t30 114605 CD HFD	inbred w/CC8	8	both	16wks	N=4	2021

Bolivar1:4	Bolivar1	open field test	(none)	number of horizontal movement episodes, 5 min test in dark [n] horiz_bouts 63404 day 1 day 2 day 3	inbred	10	both	8-14wks	N=12	2000

Bolivar1:13	Bolivar1	open field test	(none)	vertical activity (beam breaks), 5 min test in dark [n] vert_act 63413 day 1 day 2 day 3	inbred	10	both	8-14wks	N=12	2000

Bolivar1:16	Bolivar1	open field test	(none)	number of vertical movement episodes, 5 min test in dark [n] vert_bouts 63416 day 1 day 2 day 3	inbred	10	both	8-14wks	N=12	2000

Bolivar1:19	Bolivar1	open field test	(none)	percentage of time spent vertical, 5 min test in dark [%] vert_time_pct 63419 day 1 day 2 day 3	inbred	10	both	8-14wks	N=12	2000

Bolivar1:28	Bolivar1	open field test	(none)	percentage of time spent moving stereotypically, 5 min test in dark [%] stereo_time_pct 63428 day 1 day 2 day 3	inbred	10	both	8-14wks	N=12	2000

Bolivar1:40	Bolivar1	open field test	(none)	distance traveled in periphery, 5 min test in dark [cm] margin_dist 63440 day 1 day 2 day 3	inbred	10	both	8-14wks	N=12	2000

Bolivar1:52	Bolivar1	open field test	(none)	percentage of time spent in left-front of arena, 5 min test in dark [%] LF_time_pct 63452 day 1 day 2 day 3	inbred	10	both	8-14wks	N=12	2000

Bolivar1:55	Bolivar1	open field test	(none)	percentage of time spent in right-front of arena, 5 min test in dark [%] RF_time_pct 63455 day 1 day 2 day 3	inbred	10	both	8-14wks	N=12	2000

Bolivar1:58	Bolivar1	open field test	(none)	percentage of time spent in left-rear of arena, 5 min test in dark [%] LR_time_pct 63458 day 1 day 2 day 3	inbred	10	both	8-14wks	N=12	2000

Bolivar2:5	Bolivar2	fear conditioning test	(none)	percentage of baseline activity that occurred after third shock of training period [%] act_shock3_pct 63905	inbred	8	both	9-20wks	N=18	2001

Bolivar3:11	Bolivar3	monitoring system	(none)	percentage of time spent on positive social interactions, 30 min test, study 2 [%] pos_social_pct 64211	inbred	7	m	8-12wks	N=12	2007

Brown1:25	Brown1	elevated plus maze	(none)	grooming duration [s] groom_EPM 9425	inbred	14	both	10wks	N=13	2004

Brown2:52	Brown2	visual water box	(none)	visual discrimination, pattern discrimination, percent correct performance, 0.17 grating threshold, day 8 [%] pct_pat_disc_d8 22552	inbred	14	both	10-18wks	N=7	2004

Brown2:53	Brown2	visual water box	(none)	visual acuity, percent correct performance [%] pct_vis_acuit 22553 grating threshold: 0.17 (low) 0.32 0.64 (high)	inbred	14	both	10-18wks	N=7	2004

Brugnara1:8	Brugnara1	complete blood count	(none)	mean RBC corpuscular volume (MCV) [fL] MCV 47408	inbred	10	both	8wks	N=31	2013

Brugnara1:10	Brugnara1	complete blood count	(none)	mean RBC corpuscular hemoglobin conent (MCH) [pg] MCH 47410	inbred	10	both	8wks	N=31	2013

CGDpheno1:7	CGDpheno1	complete blood count	(none)	monocyte differential (MONO; percentage of total WBC) [%] pctMONO 31807	inbred w/CC8	72	both	11wks	N=7	2009

CGDpheno1:27	CGDpheno1	complete blood count	(none)	mean RBC corpuscular volume (MCV) [fL] MCV 31827	inbred w/CC8	72	both	11wks	N=7	2009

Crabbe4:11	Crabbe4	alcohol quantification	ethanol	blood ethanol concentration (BEC), 35 min post-injection, dowel (15.8 mm) test [mg/mL] BEC_dowel15_8 19111	inbred	8	both	12-16wks	N=3	2003

Crowley1:29	Crowley1	behavior observation	haloperidol	tongue protrusions, 15 min test [n] tongue 39429 day: 0 30 60 120	inbred w/CC8	27	m	9-28wks	N=6	2012

Crusio1:3	Crusio1	open field test	(none)	percentage of total time spent in center, 20 min test [%] center_time 62003	BXD w/par	55	both	10-12wks	N=8	2018

Crusio1:5	Crusio1	open field test	(none)	percentage of total time spent in thigmotaxis zone, 20 min test [%] periphery_time 62005	BXD w/par	55	both	10-12wks	N=8	2018

Crusio1:7	Crusio1	open field test	(none)	percentage of total distance run in thigmotaxis zone, 20 min test [%] periphery_dist_pct 62007	BXD w/par	55	both	10-12wks	N=8	2018

Crusio1:62	Crusio1	histopathology	(none)	percentage of hippocampus that is suprapyramidal mossy fibers [%] supra_pct 62062 left right mean	BXD w/par	55	both	12-16wks	N=4	2018

DiCurzio1:6	DiCurzio1	histopathology	(none)	adrenal total width, diameter [µm] adr_width 36606	BXD w/par	66	both	7-10wks*	N=3	2010

DiPetrillo1:1	DiPetrillo1	urinalysis	(none)	microalbumin (urine MA) [mg/dL] MA 46001	inbred w/CC7	34	m	10wks	N=13	2012

DiPetrillo1:3	DiPetrillo1	urinalysis	(none)	albumin-creatinine ratio (urine ACR) [mg/g] ACR 46003	inbred w/CC7	34	m	10wks	N=13	2012

Gould2:3	Gould2	drug and metabolite quantification	nicotine	plasma cotinine [ng/mL] cotinine 47105 acute 0.09mg dose chronic 6.3mg dose	inbred	8	m	8-12wks	N=10	2011

Gould3:1	Gould3	behavior observation	nicotine	withdrawal study group, number of grooming episodes, 20 min test [n] grooming 47301 control nicotine dose (mg) 3 6.3 12	inbred	8	m	8-12wks	N=11	2011

Graubert1:19	Graubert1	histopathology	ENU	myeloid tumor frequency rate [score] myeloid_tumor 11619 control ENU	inbred	20	both	13-68wks	N=6	2006

Hawes1:9	Hawes1	slit lamp	(none)	corneal opacity, focal [frequency rate] cornea_focal 26709	inbred w/CC7	41	both	6-7wks	N=10	2008

Hawes1:13	Hawes1	slit lamp	(none)	iris transillumination defect [frequency rate] iris_trans_defect 26713	inbred w/CC7	41	both	6-7wks	N=10	2008

HMDPpheno4:41	HMDPpheno4	fear conditioning test	(none)	contextual fear velocity, day 2 [cm/s] ctx_vel 46841	HMDP w/par	94	m	10wks	N=7	2011

HMDPpheno7:9	HMDPpheno7	metabolite quantification	(none)	liver 1,5-anhydroglucitol (1,5-AG) (16h fast), relative abundance anhydroglucitol 50209	HMDP	105	m	16wks	N=1	2014

HMDPpheno7:28	HMDPpheno7	metabolite quantification	(none)	liver threonate (16h fast), relative abundance threonate 50228	HMDP	106	m	16wks	N=1	2014

HMDPpheno7:39	HMDPpheno7	metabolite quantification	(none)	pyridoxate (16h fast), relative abundance pyridoxate 50239	HMDP	106	m	16wks	N=1	2014

Jax1:4	Jax1	body weight	(none)	body weight [g] bw 3604 age (wks): 3 4 5 6 7 8 9 10	inbred	24	both	3wks	N=40	2000

Jaxpheno1:12	Jaxpheno1	DXA	(none)	lean body tissue mass, head excluded [g] lean_wt 22412 age 8wks age 16wks	inbred	11	both		N=8	2006

Jaxpheno1:16	Jaxpheno1	DXA	(none)	percent body fat, head excluded [%] pct_fat 22416 age 8wks age 16wks	inbred	11	both		N=8	2006

Jaxpheno1:40	Jaxpheno1	DXA	(none)	whole body bone area, head excluded [cm²] bone_area 22440 age 8wks age 16wks	inbred	11	both		N=8	2006

Jaxpheno2:1	Jaxpheno2	organ weights	(none)	brain weight [g] brain 22701 age 8wks age 16wks	inbred	11	both		N=8	2006

Jaxpheno2:12	Jaxpheno2	organ weights	(none)	heart weight as percentage of body weight [%] pct_heart 22712 age 8wks age 16wks	inbred	11	both		N=8	2006

Jaxpheno3:17	Jaxpheno3	metabolic panel	(none)	creatine kinase (plasma CK) [IU/L] CK 22817 age 8wks age 16wks	inbred	11	both		N=16	2006

Jaxpheno4:3	Jaxpheno4	complete blood count	(none)	red blood cell count (RBC; per volume x 10⁶) [n/µL] RBC 22903 age 8wks age 16wks	inbred	11	both		N=17	2006

Jaxpheno4:10	Jaxpheno4	complete blood count	(none)	neutrophil count (NEUT; units per volume x 10³) [n/µL] NEUT 22910 age 8wks age 16wks	inbred	11	both		N=17	2006

Jaxpheno4:14	Jaxpheno4	complete blood count	(none)	monocyte count (MONO; units per volume x 10³) [n/µL] MONO 22914 age 8wks age 16wks	inbred	11	both		N=17	2006

Jaxpheno4:16	Jaxpheno4	complete blood count	(none)	eosinophil count (EOS; units per volume x 10³) [n/µL] EOS 22916 age 8wks age 16wks	inbred	11	both		N=17	2006

Jaxpheno4:70	Jaxpheno4	complete blood count	(none)	mean RBC corpuscular volume (MCV) [fL] MCV 22970 age 8wks age 16wks	inbred	11	both		N=17	2006

Jaxpheno4:82	Jaxpheno4	complete blood count	(none)	mean RBC corpuscular hemoglobin content (MCH) [pg] MCH 22982 age 8wks age 16wks	inbred	11	both		N=17	2006

Jones1:2	Jones1	vestibular stimulus test	(none)	latency of 1st positive response peak (P1), VsEPs waveform [µs] latency_PosPeak1 14202	inbred	18	both	5-56wks	N=4	2003

Justice2:5	Justice2	complete blood count	(none)	red blood cell count (RBC; per volume x 10⁶) [n/µL] RBC 13205	inbred	16	both	12-16wks	N=12	2002

Justice2:8	Justice2	complete blood count	(none)	mean RBC corpuscular volume (MCV) [fL] MCV 13208	inbred	16	both	12-16wks	N=12	2002

Justice2:9	Justice2	complete blood count	(none)	mean RBC corpuscular hemoglobin (MCH) [pg] MCH 13209	inbred	16	both	12-16wks	N=12	2002

Justice2:16	Justice2	complete blood count	(none)	monocyte differential (MONO; percentage of total WBC) [%] pctM 13216	inbred	16	both	12-16wks	N=12	2002

Justice2:18	Justice2	complete blood count	(none)	basophil differential (BASO; percentage of total WBC) [%] pctB 13218	inbred	16	both	12-16wks	N=12	2002

Kumar3:21	Kumar3	open field test	(none)	time spent grooming first 55 min [s] GrTime55m 112929	inbred w/CC8	62	both	8-14wks	N=20	2021

Kumar3:25	Kumar3	open field test	(none)	number of grooming events in first 55 min [n] GrBoutNum55m 112933	inbred w/CC8	62	both	8-14wks	N=20	2021

Loos1:1	Loos1	home cage monitoring	(none)	cognitive response: entries through preferred vs. non-preferred entrances into shelter preference 50701 phase (day): habituation (4) avoidance learning (5) avoidance learning (6) stability of change (7)	inbred	8	m	8-19wks	N=36	2012

Maurer1:5	Maurer1	ECG	atenolol, isoproterenol	heart rate [n/min] HR 33205 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:13	Maurer1	ECG	atenolol, isoproterenol	amplitude of P-wave [mV] P_amp 33213 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:29	Maurer1	ECG	atenolol, isoproterenol	duration P-wave [ms] P_dur 33229 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:37	Maurer1	ECG	atenolol, isoproterenol	interval RR [ms] RR 33237 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:45	Maurer1	ECG	atenolol, isoproterenol	interval QT [ms] QT 33245 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:49	Maurer1	ECG	atenolol, isoproterenol	interval ST [ms] ST 33249 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:53	Maurer1	ECG	atenolol, isoproterenol	area of P-wave [ms*mV] Parea 33253 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=9	2009

Metten2:8	Metten2	behavior observation	ethanol	withdrawal severity during 0-25h, area under curve of handling-induced convulsions scores normalized to controls [AUC] withdrawal_EtOHadj 19508	inbred	15	m	8-15wks	N=11	2005

Mills1:11	Mills1	apoptosis assessment	(none)	late apoptotic splenocytes [%] late_apoptotic 25211 6mo 12mo 20mo	inbred	30	both		N=3	2008

Mogil1:25	Mogil1	nociception assay	(none)	percent hypersensitivity threshold to capsaicin-induced thermal hyperalgesia, tail withdrawal at 47°C [%] CAP_TW 2225	inbred	12	m	6-18wks	N=5	2002

Naggert1:5	Naggert1	hormone quantification	high-fat diet	insulin [ng/mL] INS_fat18 14305	inbred w/CC7	43	both	25-27wks	N=12	2003

Paigen4:4	Paigen4	lipid profile	(none)	triglycerides (plasma, 4h fast) [mg/dL] TG 19704	inbred w/CC7	43	both	10wks	N=12	2002

Peters1:5	Peters1	complete blood count	(none)	mean RBC corpuscular volume (MCV) [fL] MCV 6205	inbred w/CC7	43	both	10wks	N=12	2001

Peters1:6	Peters1	complete blood count	(none)	mean RBC corpuscular hemoglobin (MCH) [pg] MCH 6206	inbred w/CC7	43	both	10wks	N=12	2001

Peters1:26	Peters1	coagulation test	(none)	prothrombin time (PT) [s] PT 6226	inbred w/CC7	43	both	10wks	N=11	2001

Peters4:17	Peters4	complete blood count	(none)	monocyte count (MONO; units per volume x 10³) [n/µL] MONO 24317 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:21	Peters4	complete blood count	(none)	eosinophil count (EOS; units per volume x 10³) [n/µL] EOS 24321 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:45	Peters4	complete blood count	(none)	eosinophil differential (EOS; percentage of total WBC) [%] pctEOS 24345 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:65	Peters4	complete blood count	(none)	mean RBC corpuscular hemoglobin content (MCH) [pg] MCH 24365 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:73	Peters4	complete blood count	(none)	mean RBC corpuscular volume (MCV) [fL] MCV 24373 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:77	Peters4	complete blood count	(none)	reticulocyte count (Retic) [n/L] Retic 24377 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:85	Peters4	complete blood count	(none)	reticulocyte corpuscular hemoglobin (CHr) [pg] CHr 24385 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Reed1:1	Reed1	organ weights	(none)	heart weight [g] heart 32601 weight [g] as percent of body weight [%]	inbred	28	m	29-67wks	N=12	2009

Rusyn2:42	Rusyn2	organ weights	(none)	liver weight as percent of body weight, t=2h (local parameter) [%] LW_adj2_ctrl 36142	inbred	16	m	7wks	N=3	2010

Rusyn2:47	Rusyn2	organ weights	(none)	liver weight as percent of body weight, t=2h (local parameter) [%] LW_adj2_tce 36147	inbred	16	m	7wks	N=3	2010

Sandell1:2	Sandell1	histopathology	(none)	articular cartilage wound healing at 12 wks post-injury [score] articular_12 49802	LGXSM w/par	14	both	20wks	N=6	2012

Schalkwyk1:31	Schalkwyk1	tail suspension test	(none)	TST duration of immobility, 5 min test [s] dur_immobil 34531 trial 1 trial 2	inbred	8	m	9-11wks	N=10	2010

Schoonjans1:129	Schoonjans1	biomarker quantification	high-fat diet	bile acid α-muricholic acid amount in feces, at 24 wks [ng/mL] aMCA_feces 112760 CD HFD	BXD w/par	36	m	24wks	N=5	2021

Schoonjans1:145	Schoonjans1	biomarker quantification	high-fat diet	bile acid glycolithocholic acid amount in feces, at 24 wks [ng/mL] GLCA_feces 112776 CD HFD	BXD w/par	20	m	24wks	N=2	2021

Schoonjans1:157	Schoonjans1	biomarker quantification	high-fat diet	bile acid tauro-α-muricholic acid in feces, at 24 wks [ng/mL] TaMCA_feces 112788 CD HFD	BXD w/par	36	m	24wks	N=5	2021

Schoonjans1:159	Schoonjans1	biomarker quantification	high-fat diet	bile acid tauro-β-muricholic acid amount in feces, at 24 wks [ng/mL] TbMCA_feces 112790 CD HFD	BXD w/par	36	m	24wks	N=5	2021

Schoonjans1:161	Schoonjans1	biomarker quantification	high-fat diet	bile acid taurocholic acid amount in feces, at 24 wks [ng/mL] TCA_feces 112792 CD HFD	BXD w/par	36	m	24wks	N=5	2021

Schoonjans1:163	Schoonjans1	biomarker quantification	high-fat diet	bile acid taurocholic acid amount in feces, at 24 wks [ng/mL] TCDCA_feces 112794 CD HFD	BXD w/par	36	m	24wks	N=5	2021

Schoonjans1:165	Schoonjans1	biomarker quantification	high-fat diet	bile acid taurodeoxycholic acid amount in feces, at 24 wks [ng/mL] TDCA_feces 112796 CD HFD	BXD w/par	36	m	24wks	N=5	2021

Schoonjans1:171	Schoonjans1	biomarker quantification	high-fat diet	bile acid tauroursodeoxycholic acid amount in feces, at 24 wks [ng/mL] TUDCA_feces 112802 CD HFD	BXD w/par	36	m	24wks	N=5	2021

Schoonjans1:224	Schoonjans1	organ weights	high-fat diet	kidney weight (both) [g] kidney_wt 112859 CD HFD	BXD w/par	36	m	29wks	N=5	2021

Shockley1:9	Shockley1	lipid profile	high-fat diet	triglycerides (TG, 5h fast) [mg/dL] TG 33409 control diet high-fat diet difference	inbred	10	both	10-13wks	N=5	2008

Vinyard1:7	Vinyard1	bone dimensions	(none)	height of the condyle above the molar tooth row [mm] condyle_height 30407	inbred	21	both	9-12wks	N=10	2009

Wiltshire3:19	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex FUT9, relative fluorescence intensity FUT9 38119 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:28	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GFAP, relative fluorescence intensity GFAP 38128 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:34	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GIRK3 (KCNJ9), relative fluorescence intensity GIRK3 38134 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:55	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex NGF, relative fluorescence intensity NGF 38155 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:70	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PTH, relative fluorescence intensity PTH 38170 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire4:1	Wiltshire4	immune cell quantification	BEZ235	B cells, percent viability [%] Bcells_BEZ 52401 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:21	Wiltshire4	immune cell quantification	doxorubicin	B cells, percent viability [%] Bcells_Dox 52421 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:33	Wiltshire4	immune cell quantification	doxorubicin	monocytes, percent viability [%] monocytes_Dox 52433 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:53	Wiltshire4	immune cell quantification	idarubicin	monocytes, percent viability [%] monocytes_Ida 52453 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Yuan3:56	Yuan3	metabolic panel	(none)	total protein (plasma TP) [g/dL] TP 24456 6mo 12mo 18mo	inbred	32	both		N=7	2008

List measures where DBA/2J is an outlier

Filter Table Results